PubRank

Iqbal S Grewal

Author PubWeight™ 36.04‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002 2.75
2 Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003 2.51
3 Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005 1.84
4 Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008 1.40
5 APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004 1.29
6 Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005 1.28
7 Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv Exp Med Biol 2009 1.26
8 Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2006 1.21
9 Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008 1.11
10 Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 2007 1.09
11 Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 2009 1.03
12 TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice. Immunol Cell Biol 2005 1.00
13 Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 2008 0.98
14 Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther 2007 0.98
15 Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs 2009 0.97
16 Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006 0.96
17 Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. Adv Exp Med Biol 2009 0.96
18 NTB-A, a new activating receptor in T cells that regulates autoimmune disease. J Biol Chem 2004 0.95
19 Targeting CD70 for human therapeutic use. Adv Exp Med Biol 2009 0.94
20 A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 2004 0.93
21 CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 2008 0.89
22 Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis. J Immunol 2009 0.89
23 Antibody drug-conjugates targeting the tumor vasculature: Current and future developments. MAbs 2010 0.88
24 Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma. Clin Cancer Res 2011 0.88
25 Targeting inflammatory cells to improve anti-VEGF therapies in oncology. Recent Results Cancer Res 2010 0.87
26 Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol 2003 0.86
27 CD40 expression on antigen presenting cells and correlation with disease severity in atopic dermatitis. Eur J Dermatol 2008 0.85
28 Role of L-selectin in the development of autoimmune diabetes in non-obese diabetic mice. Int Immunol 2004 0.82
29 CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity. Eur J Dermatol 2007 0.82
30 Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies. MAbs 2010 0.81
31 A crucial role of CD4 T cells as a functional source of CD154 in the initiation of insulin-dependent diabetes mellitus in the non-obese diabetic mouse. Int Immunol 2003 0.80
32 Targeting of BAFF and APRIL for autoimmunity and oncology. Adv Exp Med Biol 2009 0.80
33 Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009 0.79